Allen K B, Shaar C J
Department of Cardiothoracic Surgery, Indiana Heart Institute, St Vincent Hospital and Health Care Center, Indianapolis, IN, USA.
Semin Interv Cardiol. 2000 Jun;5(2):75-81. doi: 10.1006/siic.2000.0125.
Transmyocardial revascularization (TMR) using holmium:yttrium-aluminium-garnet (YAG) and carbon dioxide lasers has been approved by the United States Food and Drug Administration for the treatment of medically refractory angina in patients without conventional options. In prospective, randomized trials, patients who received TMR experienced improved angina, better-event free survival, and reduction in cardiac-related rehospitalizations when compared to patients remaining on medical therapy alone. In addition, TMR as an adjunct to coronary artery bypass grafting (CABG) has resulted in improved clinical status for patients who would not be completely revascularized by CABG alone.
钇铝石榴石（YAG）和二氧化碳激光进行的心肌血运重建术（TMR）已获得美国食品药品监督管理局的批准，用于治疗没有传统治疗选择的药物难治性心绞痛患者。在前瞻性随机试验中，与仅接受药物治疗的患者相比，接受TMR的患者心绞痛症状改善，无事件生存期更好，且心脏相关再住院率降低。此外，TMR作为冠状动脉旁路移植术（CABG）的辅助手段，已使仅通过CABG无法实现完全血运重建的患者临床状况得到改善。
